TD Cowen Raises GLP-1 Sales Forecast To $150B By 2030 – Industry Leaders LLY, NVO To Remain Dominant
TD Cowen expects around 59 million patients worldwide to be using GLP-1 therapies by the end of the decade, up sharply from its previous estimate of 46 million.
Stocktwits
More News
GLP-1 Drug Giants Race to Go Global With Their Obesity Pills: ETFs to Gain
Eli Lilly and Novo Nordisk are accelerating global obesity pill launches as rising GLP-1 demand puts weight-loss ETFs in focus.
Zacks
FDA Clears NVO's Higher Dose of Wegovy: Diversify With These Health ETFs
Novo Nordisk's FDA nod for higher-dose Wegovy could boost healthcare ETFs' appeal, offering diversified exposure to the obesity drug market.
Zacks
Glenmark Debuts Budget Semaglutide In India, Undercutting Ozempic By Over 80%
As the patents for semaglutide near expiry in several countries this month, India has introduced a cost-effective alternative.
Stocktwits
Eli Lilly’s Diabetes Pill Outperforms Oral Semaglutide in Phase 3 Trial
Investors are closely watching the oral GLP-1 race as competition intensifies across the sector.
Stocktwits
Novo, Vivtex Ink $2.1 Billion Deal To Develop Oral Medicines For Obesity And Diabetes
Novo Nordisk will lead global development, regulatory approval, manufacturing, and commercialization of the resulting products.
Stocktwits
Novo Looks To Ireland To Scale Production Of Wegovy Pill: Report
According to a Bloomberg report, Novo’s CEO, Mike Doustdar, said the company will expand its facility in Ireland’s midlands region to support international demand for the oral version of Wegovy.
Stocktwits
Hoth Therapeutics' GDNF Treatment Shows Superior Efficacy Over Wegovy, Ozempic In Preclinical Trial
The company announced positive preclinical results from a study evaluating GDNF as a potential treatment for obesity and metabolic-associated steatotic liver disease.
Stocktwits
HIMS New $49 Pill Lifts Stock 10%, But Why Are NVO, LLY Stocks Falling?
The company announced the launch of a compounded copy of the Wegovy weight-loss pill at an introductory price of $49 per month.
Stocktwits
Healthcare ETFs to Watch as Novo Nordisk Tumbles on Poor Sales Outlook
Novo Nordisk slides 15% on a cautious 2026 sales outlook, but buybacks, leadership moves and Wegovy expansion put its ETFs in focus.